← Eichor
Study identifier: NCT03218345 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

EUS-guided RFA for Pancreatic Neoplasms

Condition: Pancreatic Neoplasms  ·  Sponsor: Chinese University of Hong Kong

PhaseNA
Planned participants30
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersYes

About this study

Radiofrequency ablation has been used for treatment of solid neoplasms of the liver, lung, kidney and adrenal. Recently, EUS-guided RFA has become available and the device allows EUS-guided treatment of pancreatic neoplasms. The procedure has been shown to be feasible in the porcine pancreas and was used to treat small groups of patients that are not suitable for surgery suffering from pancreatic neoplasms. The aim of the current study is to perform a multi-center prospective study on EUS-guided radiofrequency ablation (RFA) of solid pancreatic neoplasms. The hypothesis is that EUS-guided RFA is safe, feasible and effective for treating solid pancreatic neoplasms.

This description comes directly from the study's public registry record.

Talk to the study team

Anthony YB Teoh, Professor  ·  26322956  ·  anthonyteoh@surgery.cuhk.edu.hk

Always discuss trial participation with your own doctor first.

Locations (1)

Department of Surgery, Prince of Wales HospitalHong Kong, Hong KongRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT03218345